Impact Biomedical completes merger, becomes wholly owned subsidiary of PubCo
IBO•Impact Biomedical became a wholly owned PubCo subsidiary on November 17, 2026, and its shareholders received 8.64 million PubCo ordinary shares, about 4.8% of PubCo's outstanding shares at closing.
1. Merger completed
Impact Biomedical became a wholly owned subsidiary of PubCo on November 17, 2026, after merging with Merger Sub. PubCo also acquired all outstanding ordinary shares of Zoar, making it a wholly owned subsidiary. Impact shareholders received 8,640,000 PubCo ordinary shares, approximately 4.8% of PubCo's outstanding ordinary shares at closing; each Impact common share converted into one PubCo ordinary share following a 1-for-12.62 reverse stock split. Shareholders approved the transaction on November 13, 2026.



